Loading current stock analysis…
Loading current stock analysis…
India
As of 12 Oct 2026, 03:30 pm
Dr. Reddy's reported that its US subsidiary, Dr. Reddy's Laboratories, Inc., received a penalty of $32,350.20 from the IRS on October 2, 2026, for a fiscal year reference misclassification during tax payment. The company assessed this as having no material impact on its financials or operations. Additionally, the USFDA completed a Pre-Approval Inspection (PAI) at the company's Pydibhimavaram manufacturing facility from October 5-7, 2026, issuing a Form 483 with two observations, which Dr. Reddy's plans to address within the stipulated timeline.
Dr. Reddy's announced on October 7, 2026, that it will release its financial results for the quarter and six months ended September 30, 2026, on Friday, October 23, 2026, following a Board Meeting. An earnings call to discuss performance is scheduled for the same day.
As of October 12, 2026, Dr. Reddy's shows a bullish daily trend with an ADX of 23.1 and a SuperTrend direction indicating 'bullish'. However, the weekly and monthly trends are indicated as 'bearish', with the weekly trend showing a negative EMA 20 slope of -5.56 and the monthly trend having an ADX of 10.26.
As of October 12, 2026, the nearest resistance level for Dr. Reddy's is at ₹1236.67, which is 0.59% above the current price. The nearest support level is at ₹1218.73, which is 0.87% below the current price.
As of 12 Oct 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Profit Before Tax | ₹552.50 crore | ₹195.10 crore | ₹1,540.90 crore | ₹1,738.50 crore | PEAK₹1,904.80 crore |
| Profit Loss For Period | ₹435.60 crore | ₹221.30 crore | ₹1,189.60 crore | ₹1,336.80 crore | PEAK₹1,409.90 crore |
| Revenue From Operations | ₹8,099.80 crore | ₹7,546.40 crore | ₹8,753.40 crore | PEAK₹8,828.30 crore | ₹8,572.10 crore |
| Expenses | PEAK₹7,902 crore | ₹7,826.70 crore | ₹7,481.30 crore | ₹7,413.70 crore | ₹6,957.60 crore |
| Tax Expense | ₹117.70 crore | -₹21.60 crore | ₹353.60 crore | ₹408 crore | PEAK₹495.10 crore |
| Segment Profit Before Tax | ₹553.30 crore | ₹199.70 crore | ₹1,543.20 crore | ₹1,744.80 crore | PEAK₹1,905 crore |
The quarter ended 30 June 2026 shows a business that recovered revenue from the previous quarter's low but remains below the level of a year ago. Expenses have continued to climb, rising significantly faster than revenue on a year-over-year basis. The result is a sharp decline in profitability compared to the same period last year, driven by a cost structure that has expanded more rapidly than sales.
Exchange disclosures and regulatory announcements for Dr. Reddy's Laboratories.
The USFDA completed a Pre-Approval Inspection (PAI) at Dr. Reddy's FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, from October 5-7, 2026, and issued a Form 483 with two observations, which the company will address within the stipulated timeline.
On October 7, 2026, Dr. Reddy's Laboratories Limited submitted a confirmation certificate to the National Stock Exchange and BSE Limited regarding the quarter ended September 30, 2026, pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that securities received for dematerialization from M/s. Bigshare Services Private Limited were verified, mutilated, cancelled, and substituted with dematerialized holdings within 15 days as required by SEBI guidelines dated January 25, 2019. This routine compliance notice contains no disclosed financial amounts or substantive business decisions.
Dr. Reddy's Laboratories Ltd. announced it will release financial results for the quarter and six months ended September 30, 2026, on Friday, October 23, 2026, following a Board Meeting. The company scheduled an earnings call for the same day at 19:30 PM IST (10:00 AM ET) to discuss financial performance, with presentation materials and call transcripts available on its website.
DR. REDDY'S LABORATORIES LIMITED has informed the Exchange about Action(s) taken or orders passed (sub-para 20) |SUBJECT: Actions initiated/taken or orders passed-XBRL
Dr. Reddy's Laboratories, Inc., a wholly owned subsidiary of Dr. Reddy's Laboratories Limited, received an IRS transcript dated September 25, 2026, on October 2, 2026, classifying $32,350.20 as a penalty for the misclassification of a fiscal year reference during tax payment. The company evaluated the incident and determined that there is no material impact on its financials, operations, or other activities. This intimation was submitted to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dr. Reddy's Laboratories will hold a Board meeting on October 23, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026. The trading window for company securities will be closed from September 24, 2026 to October 25, 2026.
Financial Results |Meeting Date: 23-Oct-2026
Dr. Reddy's Laboratories Limited will close its trading window for dealing in securities from September 24, 2026, to October 25, 2026, inclusive, under SEBI (Prohibition of Insider Trading) Regulations, 2015. This closure is implemented to facilitate the consideration and approval of the company's unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Recent market and company developments associated with Dr. Reddy's Laboratories.
FSSAI tightens online food rules, demanding expiry dates, batch numbers, photos of dark kitchens, and platform accountability amid crackdown on misbranding and unsafe practices.
India’s food regulator FSSAI is preparing tighter rules for quick-commerce platforms, including Blinkit, Instamart and Amazon Now, amid rising enforcement over food safety violations. Here's all we know…
India's food regulator, FSSAI, issued a notice to Dr Reddy's and Nestle India's joint venture for misleading claims regarding their Celevida GLP+ supplement.
stock
FIIs stepped up selling on Tuesday even as domestic institutions continued to buy, with the Nifty down nearly 7% in September so far.
Dr Reddys Laboratories Ltd is quoting at Rs 1243, up 1.8% on the day as on 12:49 IST on the NSE. The stock is up 1.58% in last one year as compared to a 7.89% slide in NIFTY and a 25.3% slide in the Nifty Pharma index.
pharma stocks
With Indian equities under pressure from high crude prices and rising bond yields, experts recommend a cautious investment approach. Focus on accumulating high-quality stocks while monitoring key factors. Tailored strategies emphasize technical analysis and sector strength amidst ongoing volatility.
Comprehensive Section Breakdown for Dr. Reddy's Laboratories
Strategic Vision: Develops, manufactures, and markets pharmaceutical products globally.
• Vertical integration of API manufacturing
• Co-development model for generics and biosimilars
• Global R&D and manufacturing network
• Localization of products for emerging markets
Dr. Reddy's Laboratories reported a sequential rebound in revenue for the quarter ended 30 June 2026, though the top line remained below the level recorded a year earlier. Expenses continued to rise, outpacing sales growth on a year-over-year basis and narrowing the gap between income and costs. This dynamic led to a sharp year-over-year decline in profitability, despite a strong sequential recovery from the previous quarter's low.
Revenue from operations for the quarter ended 30 June 2026 was ₹8,099.80 crore. This represents a 7.33% increase from the ₹7,546.40 crore reported in the preceding March quarter. On a year-over-year basis, revenue decreased by 5.51% compared to ₹8,572.10 crore in the June 2025 quarter.
Total expenses for the quarter were ₹7,902 crore. Expenses increased by 0.96% from the previous quarter and rose by 13.57% compared to ₹6,957.60 crore a year ago. Over the past five quarters, expenses have risen in each period, moving from ₹6,957.60 crore in the June 2025 quarter to ₹7,902 crore in the current quarter.
The relationship between revenue and expenses shifted materially. In the June 2025 quarter, expenses accounted for approximately 81.2% of revenue. In the June 2026 quarter, expenses consumed approximately 97.6% of revenue. The combination of lower revenue and higher expenses narrowed the margin between sales and costs, reducing profitability.
Profit Before Tax (PBT) for the quarter ended 30 June 2026 was ₹552.50 crore. This reflects a substantial sequential recovery, increasing by 183.19% from the ₹195.10 crore reported in the March 2026 quarter. However, this sequential gain did not offset the year-over-year deterioration. PBT decreased by 70.99% compared to ₹1,904.80 crore in the June 2025 quarter.
Net Profit for the period was ₹435.60 crore. Net profit increased by 96.84% from the ₹221.30 crore in the previous quarter but fell by 69.1% from the ₹1,409.90 crore reported a year ago. The results show a sequential return to higher earnings from the March quarter's low, alongside a significant year-over-year decline.
Tax expense for the quarter was ₹117.70 crore. This contrasts with a tax benefit of ₹21.60 crore in the March 2026 quarter and a tax expense of ₹495.10 crore in the June 2025 quarter. The effective tax rate for the current quarter was approximately 21.3%, calculated as tax expense divided by profit before tax. This is lower than the effective rate of approximately 26.0% recorded in the June 2025 quarter.
Finance costs for the quarter ended 30 June 2026 were ₹125.50 crore, an increase of 18.73% from the ₹105.70 crore in the March quarter. On a year-over-year basis, finance costs increased by 51.2% from ₹83 crore in the June 2025 quarter. The rise in financing expenses contributed to the overall increase in total expenses.
Segment Profit Before Tax for the quarter was ₹553.30 crore, which closely aligns with the total Profit Before Tax of ₹552.50 crore. The difference of ₹0.80 crore indicates that unallocated corporate items had a negligible impact on the reported profit.
Segment Revenue from Operations matched Total Revenue from Operations at ₹8,099.80 crore. This alignment reflects standard consolidation practices where inter-segment revenue is eliminated, ensuring that segment-level performance is representative of the consolidated results.
Category: Manufacturing
Manufactures finished formulations in oral solid dosage, injectables, and inhaler formats across chronic therapeutic areas including oncology, cardiovascular, and gastroenterology.
Category: B2B Services
Produces bulk APIs and offers custom synthesis, process development, and contract manufacturing services to global pharmaceutical clients.
Category: Manufacturing
Develops and manufactures biosimilar proteins and monoclonal antibodies primarily for oncology and autoimmune therapies.
Core Thesis: An integrated global model links chemical research, active ingredient supply, and finished generic distribution.
• Upstream API Integration: The PSAI segment manufactures Active Pharmaceutical Ingredients (APIs) in-house, providing a secure raw material supply to the Global Generics division. • Global Generics and Biosimilars Co-Development: R&D centers coordinate design platforms, streamlining process scale-up and regulatory filings for biosimilars and complex injectables. • Emerging Market Brand Localization: Regional marketing divisions localize finished product packaging and formats, marketing products as branded generics under local names. • Custom Pharmaceutical Services (CPS): The PSAI division leverages excess manufacturing capacities to supply APIs and intermediates to external pharmaceutical firms.
Reported ownership for FY2027-Q1 as of 2026-06-30.